First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC Journal Article

   

Authors:	Caicun, Z.; Solomon, B.; Loong, H. H.; Park, K.; Pérol, M.; Arriola, E.; Novello, S.; Han, B.; Zhou, J.; Ardizzoni, A.; Perez Mak, M.; Santini, F. C.; Elamin, Y. Y.; Drilon, A.; Wolf, J.; Payakachat, N.; Uh, M. K.; Rajakumar, D.; Han, M.; Puri, T.; Soldatenkova, V.; Lin, A. B.; Lin, B. K.; Goto, K.; for the LIBRETTO-431 Trial Investigators
Article Title:	First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Journal Title:	New England Journal of Medicine
Volume:	389
Issue:	20
ISSN:	0028-4793
Publisher:	Massachusetts Medical Society
Date Published:	2023-11-16
Start Page:	1839
End Page:	1850
Language:	English
DOI:	10.1056/NEJMoa2309457
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
PMCID:	PMC10698285
PUBMED:	37870973
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=173718798&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Accession Number: 173718798 -- Entry Date: In Process -- Revision Date: 20231124 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 0255562. -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/211863